BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Insilico Medicine Receives US FDA IND Clearance For AI Designed NLRP3 Inhibitor ISM8969 In Parkinson’s Disease

Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United Stat...

January 26, 2026 | News

Gene Solutions And Pangea Laboratory Partner To Advance US Clinical Validation Of Liquid Biopsy Tests

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive ...

January 22, 2026 | News

Exciva Raises EUR 51 Million Series B To Advance Phase Two Alzheimer’s Agitation Trial

Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD) ...

January 21, 2026 | News

Alamar Launches NULISAqpcr AD 5 Plex Blood Test To Advance Early Alzheimer Detection

Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launc...

January 14, 2026 | News

China Approves ArkBio Aizhida For ADHD With Rapid Onset And All Day Symptom Control

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the...

January 12, 2026 | News

Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal To Deepen Oral Inflammation Pipeline

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on ...

January 09, 2026 | News

Shanghai Ark Biopharmaceutical Secures NMPA Approval For Azstarys ADHD Treatment In China

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that China's National Medical Products Administration (NMPA) has approved the New D...

January 07, 2026 | News

Amphix Bio Secures $12.5 Million Seed Financing To Advance Neurological Therapies

Amphix Bio announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials an...

January 02, 2026 | News

NeuroSense Reports Clean Safety Profile From Phase 2 PrimeC Study In Alzheimer’s Disease

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for&nbs...

December 24, 2025 | News

UK Hospitals Adopt AI Tool MEMORI To Strengthen Early Detection Of Hospital Acquired Infections

Sanome, the health tech company behind MEMORI, an AI-powered clinical decision support tool that helps clinicians detect hospital-acquired infections (HAIs...

December 18, 2025 | News

South Korea Takes A Major Step Toward Blood Based Alzheimer’s Diagnosis With Simoa Platform Approval

Quanterix Corporation (NASDAQ: QTRX), a U.S.-based biotechnology company specializing in ultrasensitive biomarker detection, and its clinical diagnostics b...

December 12, 2025 | News

Otsuka Advances Centanafadine With FDA Filing To Bring a First in Class ADHD Therapy to Children, Adolescents, and Adults

Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a first-in-class norepinephrine, dop...

November 26, 2025 | News

Aspen Neuroscience Secures $115 Million Series C to Advance Personalised Cell Therapy for Parkinson’s Disease

Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 millio...

November 21, 2025 | News

ReviR Therapeutics Wins CIRM Grant to Advance First in Class Dual Target Therapy for Huntington’s Disease

ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced that it has been awarded a $4....

November 21, 2025 | News

Stay Connected